She has not disclosed which kind
In contrast, a subsequent larger randomized controlled trial evaluating global non-motor outcomes including cognition, mood, and quality of life, did not find statistically significant overall improvements, suggesting that the benefits of GLP-1 agonists may be more domain-specific than generalizable across all non-motor symptoms [32]
Abbreviations GLP-1: Glucagon-like peptide 1 GIP: Glucose-dependent insulinotropic polypeptide GLP-1R: Glucagon-like peptide 1 receptor GIPR: Glucose-dependent insulinotropic polypeptide receptor ASCVD: Atherosclerotic cardiovascular disease HF: Heart failure HFpEF: Heart failure with preserved ejection fraction HFrEF: Heart failure with reduced ejection fraction T2DM: Type 2 diabetes mellitus EF: Ejection fraction LVEF: Left ventricular ejection fraction LVEDV: Left ventricular end-diastolic volume LVESV: Left ventricular end-systolic volume LVSV: Left ventricular stroke volume CO: Cardiac output CI: Cardiac index BSA: Body surface area LVIDs: Left ventricular internal diameter in systole LVIDd: Left ventricular internal diameter in diastole LVFS: Left ventricular fractional shortening LVAWTs: The thickness of the left ventricular anterior wall in systole LVAWTd: The thickness of the left ventricular anterior wall in diastole LVPWTs: The thickness of the left ventricular posterior wall in systole LVPWTd: The thickness of the left ventricular posterior wall in diastole LV: Left ventricular mass RWT: Relative wall thickness LVRi: Left ventricular remodelling index AngII: Angiotensin II Veh: Vehiculum Lira: Liraglutide TZP: Tirzepatide ECG: Electrocardiography References Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al
After treatment, vehicle-treated db/db mice weighed 12.7 g (CI95%: 6.618.8) more than their non-diabetic littermates (Table 2)
